Mission Statement, Vision, & Core Values (2026) of China Meheco Group Co., Ltd.

Founded in 1983 and listed as 600056.SS, China Meheco Group Co., Ltd. has grown from the China National Medicines and Health Products Import and Export Corporation into a comprehensive healthcare platform integrating R&D, manufacturing, distribution, logistics and technical services under the controlling shareholder China General Technology (Group) Holding Co., Ltd.; driven by a mission "To create a better life with scientific and technological progress and quality services," the company anchors its strategy on pharmaceuticals and medical devices as growth engines while pursuing a vision "To grow into a world-leading, trustworthy provider of pharmaceutical and medical device products and integrated services," and operationalizes this through core values of Integrity, Inclusiveness, Innovation, Diligence, Excellence and Win-win that shape its end-to-end industry-chain presence and alignment with the Healthy China Initiative.

China Meheco Group Co., Ltd. (600056.SS) - Intro

• China Meheco Group Co., Ltd. (Ticker Symbol: 600056.SS) is a leading integrated Chinese enterprise in pharmaceuticals and medical devices, originally established in 1983 as China National Medicines and Health Products Import and Export Corporation.
• The company operates under the controlling shareholder China General Technology (Group) Holding Co., Ltd., a major state-owned conglomerate, and has evolved into a platform covering R&D, manufacturing, distribution, logistics, international trading, academic promotion, and technical services.
• China Meheco's industrial model links trade, manufacturing, and technical services with pharmaceuticals and medical devices as primary growth engines and the broader medical industry as strategic support.
• The company positions itself to align with national health strategies such as the Healthy China Initiative and aims to become a world-leading, trustworthy provider of pharmaceutical and medical device products and integrated services.

• To improve public health and quality of life by delivering safe, effective, and affordable pharmaceutical and medical device products and by providing integrated technical and service solutions across the healthcare value chain.
• To leverage international trade experience and domestic manufacturing capabilities to ensure consistent supply and accessibility of critical medicines and devices nationwide and to strategically expand global footprint.

• Be recognized as a globally trusted healthcare platform that combines research-driven innovation, high-quality manufacturing, and lifecycle services for pharmaceuticals and medical devices.
• Drive sustainable growth through digitalization of logistics and distribution, strong regulatory compliance, and continuous R&D investment focused on areas of high unmet medical need.

• Integrity and Compliance - adhere to national and international regulatory standards and ethical business practices.
• Quality First - prioritize product safety, process control, and continuous manufacturing excellence.
• Service Orientation - deliver value through end-to-end technical and academic support to healthcare institutions and partners.
• Innovation & Collaboration - invest in R&D, foster partnerships with research institutes and industry peers, and promote cross-border collaboration.
• Customer & Patient Focus - align product portfolios and services to improve accessibility and therapeutic outcomes.

• Integrated industry chain expansion - strengthen upstream R&D and downstream distribution to capture margin across the value chain.
• Medical device growth - accelerate market share in high-demand device segments while ensuring regulatory approvals and clinical support.
• International trade and exports - leverage legacy import/export operations to expand overseas revenues and diversify market risk.
• Digital logistics and supply chain resilience - modernize warehousing, cold-chain, and distribution platforms to meet hospital and retail demand efficiently.

• Comprehensive manufacturing footprint covering small-molecule APIs, finished dosage forms, and an expanding portfolio of regulated medical devices with GMP and device manufacturing certifications.
• Ongoing investments in R&D centers, clinical trial capabilities, and partnerships with domestic universities and international research entities.
• Focus on building resilient national distribution networks, including specialized cold-chain logistics for temperature-sensitive products and digital ordering systems for institutional buyers.

• State-owned controlling shareholder structure ensures alignment with national healthcare policy and regulatory priorities while subjecting the company to SOE governance standards.
• Commitment to environmental management in manufacturing, improved occupational health and safety, and enhanced transparency in corporate governance and compliance reporting.

China Meheco Group Co., Ltd. (600056.SS) - Overview

• Technological progress: prioritizes R&D, platform development, and adoption of digital tools to accelerate drug development and medical device innovation.
• Quality services: emphasizes reliable supply chains, regulatory compliance, and customer-oriented distribution and after-sales support.
• Holistic healthcare approach: integrates product innovation with service delivery to meet evolving clinical and patient needs.

• Innovation-led growth: focus on pipeline enrichment in key therapeutic areas and medical device upgrades.
• Service excellence: enhance distribution, cold-chain logistics, and hospital service programs to ensure end-to-end quality.
• Sustainable operations: align manufacturing and commercial activities with compliance, environmental standards, and social responsibility.

• Scientific rigor - evidence-based development and continuous learning.
• Patient-centricity - safety, efficacy, and access as primary metrics of success.
• Integrity and compliance - regulatory adherence and transparent governance.
• Collaboration and partnership - working across the healthcare ecosystem to deliver outcomes.
• Continuous improvement - data-driven optimization of products and services.

• R&D allocation: prioritizing platform technologies and translational programs to shorten time-to-market for prioritized compounds and devices.
• Quality systems: investments in GMP upgrades, quality management, and digital traceability to uphold service commitments.
• Commercial strategy: balancing branded generics and innovative products while leveraging distribution strengths for market coverage.
• Partnerships: collaborative projects with academic institutions and hospital systems to validate clinical value and accelerate adoption.

China Meheco Group Co., Ltd. (600056.SS) - Mission Statement

• Global leadership: scale of operations, international partnerships, and cross-border regulatory alignment to compete with top global pharma and medtech players.
• Trustworthiness: emphasis on quality assurance, regulatory compliance, and transparent supply-chain governance to strengthen stakeholder confidence.
• Integrated services: combining pharmaceutical products, medical devices, logistics, and digital health solutions to provide end-to-end healthcare offerings.
• Continuous improvement: sustained R&D investment, manufacturing upgrades, and adoption of international quality standards (e.g., GMP, ISO).

• Strengthening domestic manufacturing while expanding export channels and overseas licensing.
• Investing in innovation platforms (biologics, medical devices, digital therapeutics) to diversify revenue streams.
• Embedding trust via pharmacovigilance, post-market surveillance, and third-party quality audits.

• R&D intensity target: incremental annual growth in R&D spend to accelerate biologics and device pipelines.
• Quality and compliance metrics: reduction in product recalls and regulatory non-conformances year-over-year.
• International market expansion: increasing export share and establishing regulatory approvals in key regions (EU, ASEAN, MENA).
• Stakeholder trust indicators: higher supplier-audit scores, improved customer-satisfaction KPIs, and enhanced ESG disclosure.

China Meheco Group Co., Ltd. (600056.SS) - Vision Statement

• Provide safe, effective, and accessible medicines and healthcare services for patients domestically and internationally.
• Drive long-term shareholder value through disciplined capital allocation, operational excellence, and strategic partnerships.
• Cultivate research and development capabilities to transform scientific advances into practical therapies and healthcare innovations.

• Integrity - Upholding ethical practices, compliance, and transparency across procurement, manufacturing, and distribution.
• Inclusiveness - Fostering a diverse workplace and open collaboration across subsidiaries, partners, and communities.
• Innovation - Prioritizing R&D, clinical partnerships, and digital transformation to accelerate product and service development.
• Diligence - Emphasizing operational rigor, quality control, and continuous improvement in manufacturing and supply chain management.
• Excellence - Pursuing high standards in regulatory compliance, product quality, and customer service performance.
• Win-win - Building long-term, mutually beneficial relationships with patients, healthcare providers, suppliers, regulators, and investors.

• R&D and product pipeline expansion: targeted investment to convert scientific research into marketable formulations and branded generics.
• Distribution and logistics optimization: strengthening national cold-chain and digital ordering systems for faster, safer delivery.
• Quality and compliance: continuous GMP upgrades, auditing, and certification to meet domestic and export requirements.
• Partnerships and internationalization: licensing, joint ventures, and selective M&A to access new markets and technologies.

• Integrity - Implementing enhanced traceability systems and third-party audit frequency increases (internal KPI: 100% supplier audit coverage for high-risk suppliers).
• Inclusiveness - Diversity targets for management and cross-functional teams; employee training hours per year tracked (target >40 hours/employee).
• Innovation - Measured by yearly R&D spend and number of IND/NDA filings; pipeline milestones display calendar targets and success-rate metrics.
• Diligence - Quality KPIs such as product complaint rates, batch-release compliance (>99%), and on-time delivery (>95%).
• Excellence - Customer satisfaction surveys and hospital procurement rankings inform product and service improvement cycles.
• Win-win - Contract renewal rates with major distributors and collaborative revenue-sharing models with partners (targeted renewal >85%).

• Board oversight of ethical and compliance programs, with dedicated committees for audit, risk, and nomination.
• Performance-linked incentives aligning management compensation with long-term metrics: ESG targets, safety, and sustainable profitability.
• Public reporting cadence - annual and interim reports disclose financials, governance, and progress on strategic KPIs.